List view / Grid view
9 December 2015 | By Victoria White
The gene therapy pipeline has more than 900 products in development, and the early-stage pipeline looks particularly strong with 76% of products at either the discovery or preclinical stage...
3 September 2015 | By Victoria White
The deals market for antisense RNAi therapeutics witnessed a record year in 2014, with a total value of almost $5.6 billion across 59 transactions...
2 September 2015 | By Victoria White
In the Phase 1 study, subcutaneous administration of ALN-PCSsc resulted in an up to 83% lowering of LDL-C, with an up to 64 ± 5% mean maximum reduction, comparable to published results for anti-PCSK9 MAbs...
21 May 2015 | By Victoria White
Alnylam has filed a Clinical Trial Application to initiate a Phase 1/2 clinical trial with ALN-AAT for the treatment of alpha-1 liver disease...
14 April 2015 | By Victoria White
Preclinical results on ALN-AT3, an investigational RNAi therapeutic targeting AT for the treatment of haemophilia and RBD, have been published...
